Ask HopeStage to review this study with me
Study ID: NCT07161700. We help you review the study, but cannot decide medical eligibility.
Enrolling By InvitationNCT07161700
Safety study of SPT-300 (GlyphAllo) in depression
This study is enrolling by invitation in the United States, in Bulgaria, in Czech Republic, .... It is testing SPT-300 (GlyphAllo) for depression.
DepressionDrugFrom 18 Years to 66 Years
Key information made simple
What is this study testing?
This study is testing whether a study medication may be useful for adults experiencing depression.
What would participation involve?
Participants may receive a study medication, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in Bulgaria, Czech Republic, Germany.
Who is it mainly for?
This study appears to be mainly for adults with depression.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a lab, with sites including Seaport Investigator Site in Chino, Seaport Investigator Site in Garden Grove, and Seaport Investigator Site in Glendale. Participation appears to involve guided sessions or support activities with check-ins on how they fit into daily life. The main fit is usually having a stable enough treatment background for the study, while common reasons not to take part include pregnancy or breastfeeding and major medical issues that could make participation unsuitable. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: September 2, 2025
- Recruitment status
- Enrolling By Invitation
- Estimated enrollment
- Not clearly listed
- Sponsor
- Seaport Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States, Bulgaria, Czech Republic, ...
- Age range
- From 18 Years to 66 Years
- Official registry ID
- NCT07161700
- Official title
- An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT07161700. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Requires travel, with in-person participation in Bulgaria.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Who might this study be for?
This study may concern people with depression; age range: From 18 Years to 66 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Seaport Therapeutics, which appears to be a biotech company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The recruitment status is not clearly listed. Check the official registry or contact the study team.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
Enrolling By InvitationNCT07217860
An Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
This study is enrolling by invitation in the United States. It is testing azetukalner for depression.
Enrolling By InvitationNCT06922110
An Study of Azetukalner in Major Depressive Disorder
This study is enrolling by invitation in the United States. It is testing azetukalner for depression.
Enrolling By InvitationNCT06034821
Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan
This study is enrolling by invitation. It focuses on depression and currently lists participation information in Canada and the United States.